Thousands take part in Gaudreau Family 5K walk and run in honour of brothers John and Matthew
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
27 minutes ago
- National Post
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
Article content LEXINGTON, Mass. — Agenus Inc. ('Agenus') (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A. Article content Speakers to Include: Article content Article content Garo H. Armen, PhD Article content Founder, Chairman, CEO of Agenus Article content Jennifer Buell, PhD CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus Article content Richard M. Goldberg, MD Chief Development Officer of Agenus (joined May 2025) GI oncology expert with 40+ years in CRC research Article content Nicholas C. DeVito, MD Assistant Professor of Medical Oncology at Duke University Primarily treats patients with CRC and gastroesophageal cancers Research focused on tumor immune evasion and immunotherapy Article content Chris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG) Stakeholder Briefing Details: Webcast Link | Audience Conference Call Registration Link | Conference ID: 73242 Article content About Agenus Article content Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Article content About Botensilimab (BOT) Article content Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Article content Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit Article content About Balstilimab (BAL) Article content Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Article content Forward-Looking Statements Article content This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'potential,' 'game-changing,' 'curative,' and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the 'Risk Factors' section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Article content Article content Article content Article content Contacts Article content Investors Article content Article content 917-362-1370 |
Globe and Mail
36 minutes ago
- Globe and Mail
When should I see a doctor for sunburn?
Ask a Doctor is a series of physician-authored columns offering insights and advice on common health topics. It is not a substitute for seeking medical care. As an emergency doctor, I've seen plenty of people come to the hospital with painful sunburns – sometimes severe enough to need medical care. Many of these patients were surprised by how quickly their skin turned red after an afternoon gardening or a walk in the park. While most sunburns can be treated at home, some symptoms warrant a closer look. Here's what to do if you've already experienced sunburn – and how to protect your skin from sun exposure. Sunburn is a type of radiation burn from excessive exposure to ultraviolet (UV) rays. Your skin reacts with inflammation that ranges from varying degrees of redness and pain to blisters and peeling. Here's what you can do to help: If you notice any of the following, seek medical care right away: There are two main types of UV rays: UVA and UVB. Both cause damage to skin components and DNA, leading to tanning, burns, accelerated aging and an increased risk of skin cancer over time. You don't have to experience sunburn to sustain damage and even a single sunburn increases your lifetime risk of skin cancer. A tan also means injury, since your skin darkens in response to UV exposure to protect itself. That increased melanin production is actually a sign that DNA damage has already occurred. Sunburns and bug bites are summer rites, but you can minimize the feeling of irritation In Canada, UV levels peak between late spring and early fall, and are usually highest between 11 a.m. and 3 p.m., but UV rays don't stop outside these hours or seasons. Cloud cover does not block all UV; up to 80 per cent of rays can still reach you on overcast days. And harmful sunlight can also reach through windows or in your vehicle. If you will be spending time outside, it's important to use a sunscreen with broad-spectrum protection that shields against both UVA and UBV rays. Pay attention to the sun-protection factor or SPF number. The Canadian Dermatology Association recommends sunscreen with a SPF 30 or higher. Make sure to apply sunscreen generously 15 to 20 minutes before exposure. Be sure to reapply every two hours, and more often if sweating or swimming, and don't forget ears, neck, feet and scalp lines. For your lips, choose an SPF 30 or more lip balm, and reapply every hour. Most people don't use enough sunscreen for it to be effective. Health Canada recommends adults use about a teaspoon of sunscreen to cover each area of exposed skin (e.g. a teaspoon for each arm). For just the face and neck, aim for about 1/2 a teaspoon. Spray sunscreens are popular because of their ease of application, but it's difficult to know whether enough has been applied. If using a spray sunscreen, apply liberally until the skin is glistening, then rub the sunscreen in to get even coverage. For the head and neck, do not spray directly onto it to avoid inhaling the spray. Instead, spray a large amount onto your hands, then rub onto your face, ears and neck. Looking for sunscreen advice? Listen to the experts, not social media But remember that sunscreen alone won't protect you. Here's what I tell my patients: Dr. Shazma Mithani is an emergency physician working with adult and pediatric patients in Edmonton. Dr. Mithani is actively involved with the Canadian Medical Association, Alberta Medical Association and Sexual Assault Centre of Edmonton. She is also co-host of The Doc Talk Podcast.
National Post
38 minutes ago
- National Post
Pirates hot-head Tommy Pham levels steroids accusation in lashing out at Blue Jays
Pirates outfielder Tommy Pham may have wanted a piece of Blue Jays catcher Tyler Heineman on Monday night in Pittsburgh, but his beef with the opposition didn't stop there. Article content While the on-field incident in the bottom of the seventh inning caused both dugouts to empty, the social media volleys continued well into the night with Pham lashing out at both Heineman and Jays outfielder Addison Barger. Article content Article content Pham went to social media site X to take umbrage to Heineman's version of events and that's where the dispute took a turn towards ugly. In a response to another user, in a post he's since deleted, the controversial Pirates veteran accused Barger of taking steroids. Article content The on-field incident with Heineman began after Pham was walked in the seventh inning of the Pirates 5-1 win. The situation was muted quickly, even after both dugouts emptied but picked up steam following the game. Article content Article content 'I don't even know him,' Heineman told reporters in Pittsburgh of the incident in which Pham flipped his bat immediately after being issued the walk. 'No idea. Barely know who he is. It was weird, man. It was unprovoked and super weird.' Article content Once Pham got wind of those comments, he went off. Responding to reporter Keegan Matheson's posting of Heineman's remarks on X, Pham escalated the drama. Article content Pham clearly had a different version of events than the Jays backup catcher of the call on the field. Article content 'Bitching about a ball not being called a strike to the umpire when it's clearly below the zone and away is disrespectful not only to the umpire but the hitter as well, so like I said when I flipped the bat, f*** him,' Pham posted on X in response to Heineman's version of events. Article content Tommy Pham took to X to tell his side of the debacle. 😳 — theScore (@theScore) August 19, 2025 Article content Predictably, those comments provoked some mayhem on X. When a user who appears to be a Jays fan — with an Addison Barger picture on his profile — ripped him, Pham fired back. Article content 'Your profile pic is of someone who takes steroids, loser,' he posted in the since deleted post. Article content Things continued to escalate and Pham responded to more of those ripping him with a screen shot from a 2019 TSN article from 2023 that reported Barger had a PED suspension in 2019. Article content The incident, particularly the post-game commentary, certainly turned what appeared to be a quiet series against the last-place Pirates into a potentially more heated one. Article content
